In consensus molecular subtypes (CMS) of CRC (HR = 0.37, 95% CI 0.19‐0.71, p = .003), patients with BRAF mutations in CMS1 subtype exhibited a more favourable prognosis (Figure 2D). This evidence concerns the gene BRAF and colorectal carcinoma.